ASX:BNO Bionomics (BNO) Stock Price, News & Analysis → top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (From Traders Agency) (Ad) Free BNO Stock Alerts Add Compare Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolume386,458 shsAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Bionomics alerts: Email Address Ad Traders Agencytop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution… About BionomicsBionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder. It also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. Bionomics Limited was incorporated in 1996 and is based in Eastwood, Australia.Read More Ad Traders Agencytop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution… BNO Stock News HeadlinesDecember 18, 2023 | investing.comBionomics ADR (BNOX) Earnings Dates & ReportsJuly 3, 2023 | finance.yahoo.comBionomics Announces Key Leadership Updates to Drive U.S.-Focused Transformation and Next Stage of Strategic GrowthApril 25, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.March 9, 2023 | finanznachrichten.deBionomics Ltd: Bionomics Reports Promising Full Results Analysis from PREVAIL Phase 2 Study of BNC210 Social Anxiety Disorder (SAD)February 24, 2023 | finance.yahoo.comBionomics First Half 2023 Earnings: AU$0.012 loss per share (vs AU$0.013 loss in 1H 2022)February 23, 2023 | finanznachrichten.deBionomics Ltd: Bionomics' Half-Year ReportFebruary 5, 2023 | finance.yahoo.comWill Bionomics (ASX:BNO) Spend Its Cash Wisely?December 27, 2022 | finance.yahoo.comAll Focus Shifts To Bionomics' PTSD Study After Anxiety Trial DisappointsApril 25, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.December 18, 2022 | finance.yahoo.comBionomics Reports Topline Results in PREVAIL Phase 2 Study of BNC210 in Social Anxiety DisorderNovember 16, 2022 | finance.yahoo.comBionomics Limited Announces Pricing of Underwritten Offering of American Depositary Shares in the United StatesOctober 25, 2022 | finance.yahoo.comQuarterly Activities Report for September 2022October 18, 2022 | finance.yahoo.comBionomics Receives R&D Tax Incentive Refund for FY2022 of A$4.6 millionOctober 7, 2022 | finance.yahoo.comBionomics (ASX:BNO) adds AU$20m to market cap in the past 7 days, though investors from five years ago are still down 84%October 4, 2022 | finance.yahoo.comBionomics Limited to Participate in the Cantor Neurology & Psychiatry ConferenceSeptember 24, 2022 | reuters.comBNO.AX - Bionomics Ltd | Stock Price & Latest News | ReutersAugust 30, 2022 | finance.yahoo.comDoes Bionomics Limited Unsponsored ADR (BNOX) Have the Potential to Rally 329% as Wall Street Analysts Expect?August 27, 2022 | finance.yahoo.comWe're Keeping An Eye On Bionomics' (ASX:BNO) Cash Burn RateJuly 8, 2022 | finance.yahoo.comBionomics to Participate in William Blair’s Biotech Focus Conference 2022June 13, 2022 | fool.com.auHere’s why these 4 ASX shares are soaring todayJune 13, 2022 | fool.com.auWhy these 4 ASX shares have sunk lower todayJune 13, 2022 | finance.yahoo.comBionomics Investor WebinarJune 10, 2022 | finance.yahoo.comBionomics Limited (BNO.AX)May 16, 2022 | finance.yahoo.comBionomics Limited to Participate in Upcoming Investor ConferencesMay 11, 2022 | finance.yahoo.comNovamind to Host Bionomics’ PREVAIL Trial for Acute Treatment of Social Anxiety DisorderFebruary 23, 2022 | finance.yahoo.comBionomics' Half-Year ReportJanuary 14, 2022 | benzinga.comBionomics Limited (Nasdaq: BNOX, ASX: BNO) to...See More Headlines Receive BNO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bionomics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/15/2019Today4/25/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeASX SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolASX:BNO CUSIPN/A CIKN/A Webwww.bionomics.com.au Phone+61-8-83546100FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)A($0.02) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-24,910,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-46.14% Return on Assets-20.98% Debt Debt-to-Equity Ratio1.29 Current Ratio9.05 Quick Ratio12.02 Sales & Book Value Annual Sales$6.02 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow2.69 Book ValueA$0.03 per share Price / BookN/AMiscellaneous Outstanding Shares1,470,000,000Free FloatN/AMarket CapN/A OptionableNot Optionable Beta2.13 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesMr. Adrian Hinton BEC (Age 70)F.C.A., Financial Controller Comp: $323.78kDr. Spyridon Papapetropoulos M.D. (Age 50)Ph.D., CEO, Pres & Director Mr. Timothy M. Cunningham CPA (Age 60)CPA, M.B.A., Chief Financial Officer Prof. Paul Rolan D.C.P.S.A.F.F.P.M., F.R.A.C.P., M.B.B.S., M.D., Consultant Chief Medical Officer of Clinical NeuroscienceDr. Julie Kerner Ph.D.Sr. VP of Bus. OperationsDr. Atul R. Mahableshwarkar DFAPAM.D., Acting Chief Medical OfficerMs. Suzanne Irwin B.Com.FCIS, Company Sec.More ExecutivesKey Competitors180 Life SciencesNASDAQ:ATNFW3SBioOTCMKTS:TRSBF45525 (CUR.TO)TSE:CUR60 Degrees PharmaceuticalsNASDAQ:SXTPWAbcamOTCMKTS:ABCZFView All Competitors BNO Stock Analysis - Frequently Asked Questions How were Bionomics' earnings last quarter? Bionomics Limited (ASX:BNO) issued its earnings results on Friday, February, 15th. The company reported ($0.02) earnings per share for the quarter. What other stocks do shareholders of Bionomics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Bionomics investors own include ACADIA Pharmaceuticals (ACAD), Adverum Biotechnologies (ADVM), Aimmune Therapeutics (AIMT), ANI Pharmaceuticals (ANIP), AxoGen (AXGN), Biohaven (BHVN), bluebird bio (BLUE), Blueprint Medicines (BPMC), Calithera Biosciences (CALA) and Codexis (CDXS). This page (ASX:BNO) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersHe Is Giving Away BitcoinCrypto Swap Profitstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersThe #1 Crypto for 2024InvestorPlaceDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill Publishing Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bionomics Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
